{"output": [["Palatin Technologies", "ORG", "Announce", "FDA has notified Palatin", "ORG/GOV"], ["Palatin Technologies", "ORG", "Operate_In", "Biopharmaceutical Company", "ORG"], ["FDA", "ORG/GOV", "Has", "Notice to Proceed", "CONCEPT"], ["Palatin", "ORG", "Submit", "IND Application", "CONCEPT"], ["Palatin Technologies", "ORG", "Expects", "Commence Phase 1 Study", "CONCEPT"], ["PL-8177", "PRODUCT", "Is_Member_Of", "Clinical Development Candidates", "CONCEPT"], ["PL-8177", "PRODUCT", "Potential Treatment", "Patients with Ulcerative Colitis", "GPE"], ["PL-8177", "PRODUCT", "Selective Melanocortin Receptor 1 (MC1r) Agonist Peptide", "CONCEPT"], ["Palatin Technologies", "ORG", "Develop", "Melanocortin Based Therapeutics", "CONCEPT"], ["PL-8177", "PRODUCT", "Cyclic Peptide", "CONCEPT"], ["PL-8177", "PRODUCT", "Demonstrated Efficacy", "Animal Inflammatory Bowel Disease Models", "CONCEPT"], ["Palatin Technologies", "ORG", "Develop", "Oral Formulation of PL-8177", "CONCEPT"], ["Palatin Technologies", "ORG", "Maximize", "Commercial Potential", "CONCEPT"]], "published": "2018-01-03T15:30:00.000+02:00"}